High Response Rate to Carboplatin-Paclitaxel-Cetuximab and Pembrolizumab in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
The management of R/M HNSCC is rapidly evolving with new available treatment molecules and combination modalities. Anti-EGFR cetuximab (CTX) and immune checkpoint inhibitors (ICI) can be used either alone or in combination with conventional platinum-based doublet chemotherapy (with taxanes or fluoro...
Na minha lista:
| Principais autores: | , , , , , , , , |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Karger Publishers
2023-01-01
|
| 叢編: | Case Reports in Oncology |
| 主題: | |
| 在線閱讀: | https://www.karger.com/Article/FullText/528326 |
| 標簽: |
沒有標簽, 成為第一個標記此記錄!
|